Article
Effective Treatment of a BRAF V600E-Mutant Epithelioid Glioblastoma Patient By Vemurafenib: A Case Report
2020-11-23
Abstract excerpt
<title>Abstract</title> <p><bold>Background:</bold> Novel therapeutic targets in epithelioid glioblastoma (E-GBM) patients are urgently needed. About half of these tumors show the point mutations of the B-Raf proto-oncogene (BRAF). Therefore, this is a target of special interest for this group of patients. Meanwhile, unlike conventional glioblastoma, E-GBM lacks specific prognostic markers.<bold>Case presentation...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 079ce75a-5408-5ae0-a28e-a49298ecc59d
- DOI
- 10.21203/rs.3.rs-112130/v1
